Comparative Analysis of Immunomodulatory Therapies for Multisystem Inflammatory Syndrome in Children

Written By: user

IJCP Editorial Team

Published On: 21 Jul, 2023 2:32 PM | Updated On: 21 Jul, 2023 3:54 PM

Comparative Analysis of Immunomodulatory Therapies for Multisystem Inflammatory Syndrome in Children

Several studies examining the initial treatment options for multisystem inflammatory syndrome in children (MIS-C) have generated contradictory findings. The present study compared the outcomes of MIS-C patients who received intravenous immunoglobulin (IVIG), glucocorticoids, or a combination of both. The study encompassed randomized or observational comparative studies that involved MIS-C patients under 21 years of age and looked for cardiovascular dysfunction (CD), which was defined as a left ventricular ejection fraction below 55% or the need for vasopressors beyond the second day of initial therapy.

The study observed-

Identification of 2635 studies and inclusion of 3 nonrandomized cohorts.
Inclusion of 958 children in meta-analysis.
IVIG plus glucocorticoids group showed improved CD as compared with IVIG alone.
Glucocorticoids alone group did not show improved CD as compared with IVIG alone.
Glucocorticoids alone group did not show improved CD as compared with IVIG plus glucocorticoids.
Improved outcomes with IVIG plus glucocorticoids compared with glucocorticoids alone (fever ≥ day 2, need for secondary therapies) and better outcomes associated with glucocorticoids alone compared with IVIG alone (left ventricular ejection fraction < 55% ≥ day 2).

Based on a comprehensive meta-analysis of patients with multisystem inflammatory syndrome in children (MIS-C), the combination of intravenous immunoglobulin (IVIG) and glucocorticoids demonstrated a significant improvement in cardiovascular dysfunction (CD) when compared to IVIG alone. However, the administration of glucocorticoids alone did not show any significant improvement in CD compared to either IVIG alone or the combination of IVIG and glucocorticoids.

Ouldali N, et al. Immunomodulatory Therapy for MIS-C. Pediatrics July 2023; 152 (1): e2022061173. 10.1542/peds.2022-061173

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.